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ABSTRACT 
Objective: The goal of the present investigation was to improve the solubility and bioavailability of atovaquone tablet, using in-house 
biosynthesized biosurfactant in the ternary system of solid dispersion containing hydrophilic polymers with varying concentrations of 
biosurfactant. Atovaquone is an anti-malarial agent and belongs to biopharmaceutical classification system class IV. 
Methods: The solid dispersion of binary and ternary mixture was prepared using hydroxyl propyl methyl cellulose (HPMC) and biosurfactant 
respectively by a solvent evaporation method. All the atovaquone tablet formulations were prepared by incorporation of physical mixture, binary 
and ternary solid dispersed products with excipients by direct compression method. Pre-compression and post-compression parameters of 
atovaquone tablets were evaluated. In vivo bioavailability study was performed using female albino rabbits. 
Results: In vitro dissolution profile of binary and ternary system of solid dispersion products showed 8.65% and 34.64% respectively. 
Precompression and post-compression values of all atovaquone tablets formulations were within the specified limits. In vitro dissolution efficiency 
of F2 and F5 were 1.44 fold and 6.62 fold respectively, in accordance to the F1. In vivo study revealed that bioavailability of optimized formulation 
F5 was increased by 2.5 times and time to reach peak concentration was reduced to 1.4 h, in accordance to pure atovaquone suspension. 
Conclusion: Potential application of biosurfactant in the solid dosage form of atovaquone tablet was proved for enhanced dissolution rate and 
bioavailability of atovaquone for malaria treatment.  
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Atovaquone is unique naphthoquinone with a broad-spectrum 
antiprotozoal agent, belongs to the biopharmaceutical classification 
system (BCS) class IV and exhibits low and variable oral bioavailability 
(46%) due to its poor aqueous solubility (less than 0.25µg/ml) [1]. 
Enhancement of dissolution and thereby its bioavailability is a primary 
requisite of an oral drug delivery of atovaquone. Numerous technologies 
have been developed for enhanced solubility of poorly water-soluble 
drug such as micronization, salt-formation, solid dispersion, 
complexation etc. Solid dispersion using a water-soluble carrier system 
is the most commercially viable technology applicable in recent years. 
The ternary system of solid dispersion is the addition of surfactants in a 
binary system and also plays essential processes of modification for 
maximum solubility of the drug in the aqueous fluid [2]. 
Nonionic surfactants were used for enhancement of solubility of 
poorly water-soluble drug in the range of 5%w/w to 20%w/w. 
Synthetic surfactants are non-biodegradable. In recent years novel 
biotechnological products are produced from various micro-
organisms through fermentation. Biosurfactants are produced from 
specific microorganisms with economic substrates such as waste 
fried oils, molasses etc, in a suitable media and environmental 
conditions. Major advantages of biosurfactants over the synthetic 
surfactants are, at low concentration maximum solubility of poorly 
soluble drugs, stable in all pH range, very less toxicity and 
biodegradability. This is due to its unique chemical composition with 
fatty acid, monosaccharide and amino acids [3, 4]. 
From the literature survey, it was revealed that the potential application 
of biosurfactant has not been explored as a solubility modulator and 
permeability catalyst for in-soluble and less permeable drugs. In this 
study, atovaquone drug was selected as model drug for its enhancement 
of solubility and permeability. The aim of our present study was to 
formulate atovaquone tablet of the physical mixture, binary and ternary 
solid dispersion system using water-soluble carrier hydroxyl propyl 
methyl cellulose (HPMC) with biosurfactant and compare its dissolution 
rate and bioavailability with poloaxmer 407 a nonionic surfactant.  
MATERIALS AND METHODS 
Materials 
Gift sample of atovaquone was procured from Matrix Lab Ltd 
Hyderabad. Poloaxmer 407 from venous ethoxy ether Pvt Ltd, Goa. 
Hydroxypropyl methyl cellulose (HPMC) from Colorcon industry, 
Goa. Lactose, polyvinyl pyrrolidone (PVP), magnesium stearate and 
talc from Balji chemicals, Mumbai. All other chemicals were from SD 
fine chem India (AR grade). 
Methods 
In-house biosynthesis of biosurfactant 
Biosurfactant was produced from the biotechnology processes using 
Flavobacterium Sp 2495(Chandigarh) in a modified mineral salt media. 
Molasses 5%w/v, waste fried oil 5%w/v and 1%w/v peptone, 0.5%w/v 
ammonium chloride were used as carbon and nitrogen source 
respectively. Trace elements were ferric chloride and vitamin B6. 
Fermentation conditions were maintained at pH at 7.4, temperature 
32±1 °C, aeration 40% and rpm 150. Duration of fermentation was 72 h 
(sorotus lite fermentor). The fermented fluid was separated by solvent 
extraction using a methanol-water mixture (1:2). Purification was 
carried out using 5N hydrochloric acid (HCl) by the precipitation 
method. The product was dried at 40 °C for 3 h and passed through 60 
mesh and stored in an airtight container at room temperature. An oral 
toxicity study was performed on albumin rats as per organization for 
economic co-operation and development (OECD) guidelines. It was 
found that 2000 mg per kg body weight of albumin rats was safe without 
mortality and toxicity. The yield of biosurfactant was 2.5g per liter [5]. 
Preformulation studies 
Compatibility studies 
Compatibility study of drug and excipients was carried out through 
fourier transmission infrared spectrophotometer (FTIR) (Shimadzu 
Japan) using potassium bromide (KBr) probe technique, scanned from 
4000-400 cm-1. Graphs were recorded and analyzed for comparatively 
for compatibility studies. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 11, Issue 2, 2019 
Bolmal et al. 
Int J App Pharm, Vol 11, Issue 2, 2019, 44-49 
 
45 
The solid dispersion of atovaquone with HPMC and bio 
surfactant 
Solvent evaporation technique was adopted for the preparation of 
the solid dispersion product. Atovaquone was dissolved in ethanol. 
Hydroxyl propyl methyl cellulose was dissolved in water in the ratio 
1:2 (drug: polymer) using a magnetic stirrer. The drug solution was 
added to the aqueous hydroxyl propyl methyl cellulose solution with 
constant stirring. The ternary system was prepared by adding 
various concentrations of surfactants to the drug-polymer solution 
as shown in the table 1. The mixture was evaporated on 8 cm 
diameter china dish for 48 h at room temperature. The solid mass 
obtained was dried at 40 °C in the oven for 4 h, pulverized, sieved 
through 60 mesh and stored in an airtight container until use [6, 7]. 
 
Table 1: Solid dispersion of atovaquone with hpmc and surfactants 
Ingredients    Formulation code 
Unit S0 S1 S2 S3 S4 S5 S6 S7 
Atovaquone mg 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 
HPMC mg ---- 125 125 125 125 125 125 125 
Biosurfactant mg ---- -- 2 4 6 - - --- 
Poloxamer407 mg ---- -- -- - - 10 20 30 
Ethanol ml ---- 30 30 30 30 30 30 30 
 
Preparation of atovaquone tablet using the solid dispersed product 
Compressed tablets containing physical mixture and solid dispersed 
product with and without surfactants were prepared separately by 
direct compression method. Diluent lactose, dry binder polyvinyl 
pyrrolidone, and lubricants talc, magnesium stearate were used as 
excipients. All ingredients were sieved through 40 mesh and 
blended with lubricants and compressed in 10 stations rotary 
machine (M/s Karnavati) at 6 kg/cm2 hardness using 9 mm flat 
punches. All the formulation batches were shown in the table 2. 
 
Table 2: Formulation of atovaquone tablets 
Ingredients (mg) Formulation code 
F1 F2 F3 F4 F5 F6 
Atovaquone  62.5 62.5 62.5 -- -- -- 
Solid dispersion system  --- --- --- S1 S3 S7 
Biosurfactant  -- 4 -- -- -- -- 
Poloxamer407  --- -- 30 -- -- -- 
Lactose  159.5 155.5 129.5 34.5 30.5 4.5 
PVP  5 5 5 5 5 5 
Mg stearate  1 1 1 1 1 1 
Talc  2 2 2 2 2 2 
Total weight  230 230 230 230 230 230 
S1, S3, S7. Solid dispersed products 
 
Evaluation of atovaquone solid dispersed products 
In vitro dissolution 
All solid dispersion products and pure drug were subjected for 
dissolution profile using USP dissolution apparatus (Electro lab 
India TD 80) at 50 rpm in 1.2 pH buffer media for 1 h. Sample 
equivalent to 62.5 mg of atovaquone was placed in the tea bag and 
tied to the paddle. Aliquot samples were withdrawn from 900 ml at 
specified intervals and analyzed using uv-vis spectrophotometer 
(UV 1900 Shimadzu Japan) at λmax 220 nm under sink condition [8]. 
Evaluation of atovaquone tablets  
Pre-compression 
All the formulation of atovaquone lubricated powder blends was 
subjected for micromeritics properties using conventional methods. 
Bulk density and tapped density was determined by using 
measuring cylinder method. Hausner's ratios, Carr’s index, were 
determined using the bulk density and tapped density data. An angle 
of repose was determined by conventional funnel method [9]. 
Post-compression 
All batches of atovaquone tablets were subjected to non-
pharmacopieal and pharmacopieal tests. Tablet thickness, hardness, 
was determined using a vernier caliper and Monsanto hardness 
tester respectively. Friability, disintegration test was performed as 
per Indian pharmacopeia (IP 2014) [10]. 
In vitro dissolution rate study 
The dissolution rate of atovaquone tablets prepared was studied in 
900 ml of acidic buffer of pH 1.2 using USP dissolution apparatus 
type I at 50 rpm and the 37±1 °C temperature was maintained 
throughout the study. Aliquot samples of dissolution media (5 ml) 
were withdrawn through a filter (0.45µ) syringe at different intervals 
of time up 60 min. All the samples were suitably diluted and assayed at 
λmax 220 nm and sink condition was maintained [11, 12]. 
Dissolution efficiency 
The concept of dissolution efficiency (DE) was proposed by Khan 
and Rodes in 1975 is defined by   
 
Where Y is the percentage of drug dissolved at any time t, Q100 is the100 
percentage of dissolved product, DE is the area under the dissolution 
curve between time points 0 and t expressed as a percentage of the 
curve at maximum dissolution, Q100, over the same time period [13]. 
In vivo bioavailability study  
Experiments were conducted in compliance with the committee for the 
purpose of control and supervision of experiments on animals (CPCSEA) 
and experimental protocol approval from institutional animal’s ethics of 
our institution (Registered No221). Female albino rabbits (1.2 to 1.5 kg) 
were used in the study. Animals were divided into two groups. Each 
group containing three rabbits was housed in polypropylene cages in a 
room with the controlled temperature of 25±3 °C and relative humidity 
(RH) 60±5% in 12 h light/12 h night cycle. The animals were fed with a 
standard pelleted diet and purified water ad libitum throughout the 
experiment. Group I and group II received atovaquone (25 mg/kg) oral 
suspension and optimized atovaquone tablet formulation (F5) 
respectively, through oral silicon tube after 12 h fasting. Blood samples 
were collected from the marginal vein of the ear of rabbits at an interval 
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0.5 h, 1 h, 3 h, 6 h, 12 h in a heparinized tube. Plasma samples were 
obtained by centrifuged at 5000Xg for 10 min and stored at-20 °C until 
analyzed. All the plasma samples were analyzed for drug content 
through high-performance liquid chromatography (HPLC SPD-M20A 
Shimadzu) with the following conditions. Chromatographic separation 
was developed for the quantitative serum level of atovaquone using 
column C18. Mobile phase consists of 0.1%v/v formic acid and methanol 
in the ratio of 20:80. The aqueous phase was eluted at a flow rate of 1 
ml/min, volume injected was 20 µl and retention time was 7 to 8 min 
with the 15 min run time. The effluent was monitored at UV 254 nm. 
Standard calibration was constructed by spike method using a different 
concentration of drug in serum. All other chromatographic separation 
conditions were kept constant [14]. 
Pharmacokinetic analysis of data 
The obtained data were expressed as mean±SEM. Student t-test and 
ANOVA were used to analyze and compare the results p ˂  0.05 was 
considered significant in all the tests. Systat 13 software was used in 
the study. 
Maximum peak plasma concentration (Cmax) and time to reach 
maximum plasma concentration (t max) were obtained from the 
plasma concentration v/s time graph, area under the curve (AUC) 
calculated from the trapezoidal rule [15]. 
RESULTS AND DISCUSSION 
Drug and excipients compatibility study 
The FTIR graph interpretation of atovaquone and excipients showed 
the characteristics peaks of atovaquone at 3375 cm-1(C-O 
stretch),1658 cm-1(aromatic C=O stretch),729.09 cm-1(C-Cl 
stretch),2924(aromatic C-H stretch) were retained. No significant 
differences were observed, indicative of compatibility with drug and 
















































































































































Fig. 1: FTIR of atovaquone and excipients 
 
Solid dispersion of atovaquone 
The dissolution medium in United State pharmacopeia (USP) for 
atovaquone drug is isopropyl alcohol 40% v/v with potassium 
hydrogen phosphate pH 8. In the present study 0.1N hydrochloric 
acid pH 1.2 dissolution medium was used to mimic the biological 
fluid. All the formulated solid dispersion batches, dissolution rate 
profiles were shown in the fig. 2. Batch S1 showed two fold increases 
in dissolution rate in accordance with batch S0. All the formulation 
batches of ternary systems of biosurfactant showed an average two-
fold increase in the dissolution rate as compared to all batches of 
poloaxmer 407. Enhanced percentage of dissolution rate of 
atovaquone drug could be the effective penetration and wettability 
by biosurfactant, a similar study was reported by Swati S et al. [16]. 
Dissolution rates of batch S3 and S4 did not show significant 
differences in the percentage of drug release. Hence S3 formulation 
was chosen for further study. A comparative dissolution profile of 
binary and ternary systems of solid dispersion is shown in fig. 3. 
 
 
Fig. 2: Comparative dissolution profile of solid dispersed products from S0 to S7 for 1h. (n=3)(mean±SD) 
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Fig. 3: Comparative dissolution profile of binary (S1) and ternary system of solid dispersion (S3, S7). (n=3) (mean±SD) 
 
Atovaquone tablet evaluation 
Atovaquone tablets formulations were prepared from the physical 
mixture (F1, F2, F3) and solid dispersed product blends of binary 
(F4) and ternary systems (F5, F6) using the dry granulation method. 
These two processing steps (physical mixture and solid dispersion) 
were adapted to atovaquone tablet preparation, to evaluate the 
appropriate method of addition of surfactants to achieve an 
enhanced dissolution rate of atovaquone.  
Pre-compression 
All the formulated atovaquone formulation powder blends were 
subjected for micromeritics properties. The compressibility 
index, Hausner's ratio, and angle of repose were within the 
specified limits of 10.8% to 12.19%, 1.11 to 1.27 and 25.60 to 
28.30 respectively. From table 3 results indicates that all 
formulations were having a good free flowing and compressible 
properties. 
 













* Hausner’s ratio Angle of repose* 
 
* 
F1 0.49±0.02 0.55±0.02 12.19±0.03 1.13±0.08 25.60±2.07 
F2 0.48±0.01 0.54±0.04 10.83±0.04 1.11±0.07 26.71±0.57 
F3 0.47±0.09 0.55±0.03 10.89±0.04 1.12±0.04 27.13±0.75 
F4 0.48±0.08 0.53±0.02 13.01±0.01 1.13±0.04 26.40±0.43 
F5 0.47±0.01 0.53±0.02 11.70±0.07 1.10±0.02 27.58±0.35 
F6 0.48±0.03 0.53±0.04 10.93±0.09 1.13±0.09 28.30±0.01 
*mean±SD (n=6) 
 
Table 4: Post-compression parameters 








Disintegration time (min)* 
F1 230±2.01 3.5±0.5 3.3±0.35 0.32±0.091 98.22±0.50 7.50±0.01 
F2 230±3.04 3.5±0.6 3.5±0.50 0.39±0.015 96.70±1.06 5.5.±0.04 
F3 230±3.25 3.5±0.5 3.3±0.35 0.36±0.028 99.05±0.43 6.60±0.25 
F4 230±2.02 4.5±0.5 3.4±0.40 0.19±0.041 98.03±0.37 6.30±0.02 
F5 230±3.05 4.25±0.5 3.3±0.35 0.21±0.028 97.45±0.43 4.50±0.05 




Pharmacopieal and non–pharmacopieal tests for atovaquone tablets 
results were shown in the table 4. Weight variation test, thickness, 
hardness, friability, and drug content results were within the 
specified limits. Results of disintegration test for batch F2 and F5 
indicated that addition of biosurfactant in the ternary system can 
improve the disintegration time. Similar results were also reported 
by Shaji A et al. [17]. 
In vitro dissolution profile 
In vitro dissolution of a physical blend of atovaquone tablets F1, F2 
and F3 showed 5.7%, 9.0% and 7.23% drug release respectively. 
Binary and ternary blend system atovaquone tablets, F4, F5 and F6 
showed 10.95%, 37.65% and 18.64% respectively (fig. 4). The 
numbers of fold increase in dissolution efficiency for F2, F3, F4, F5, 
and F6 were 1.44, 1.28, 1.94, 6.62, and 3.51 respectively (table 5). In 
vitro dissolution profile revealed that physical mixture blend(F2) 
and the ternary system blend (F5) of biosurfactant showed 2 fold 
and 6.6 fold an increase in the percentage of dissolution rate 
respectively, calculated at DE45. From these results conclude that 
the most effective step for the addition of surfactant in the tablet 
formulation was in the ternary system. Mohamed FK et al. [18] 
reported that addition of surfactant in ternary solid dispersion 
system showed an increased in dissolution rate of less water-soluble 
drug.
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Fig. 4: In vitro dissolution of atovaquone tablet F1 to F6. (n=3) (mean±SD) 
 
Table 5: Dissolution efficiency of F1 to F6 (n=3) (mean±SD) 
Formulation F1 F2  F3 F4   F5  F6 
DE45 5.02±5.3 7.2±6.8  6.45±7.2 9.75±5.8 33.25±4.8  17.65±5.6 
No of fold increase in dissolution rate --- 1.44 1.28 1.94 6.62  3.51 
 
In vivo study 
From in vivo data, model-independent pharmacokinetic parameters, 
Cmax, tmax, and AUC were summarized in the table 6. The mean AUC 
of F5 and oral suspension were 240.73 µg/ml/h and 88.71 µg/ml/h 
respectively. Formulation F5 exhibited a significant increase Cmax: 3 
folds and tmax was shortened by 1.4h in accordance to oral 
suspension (fig. 5). Formulation strategy for BCS class IV drug has 
been met with moderate success by incorporation of biosurfactant in 
the atovaquone dosage form. The beneficial effect of biosurfactant 
could be enhanced solubility-dissolution kinetics is the probable 
driving force behind the improved pharmacokinetic properties and 
effective softening of tight junction of the intestinal cell lining. 
Improved bioavailability study was reported by Borhardev et al. [19]. 
 
Table 6: In vivo study of F5 and oral suspension 
PK parameters Oral suspension F5* * 
Cmax µg/ml 10.56±12.51 30.12±14.32 
t max h  6.5±14.32 5.1±13.58 




Fig. 5: In vivo study of F5 and atovaquone suspension. (n=3) (mean±SD) 
 
CONCLUSION 
The main objective of the present study was to evaluate the effect of 
biosurfactant on dissolution rate and bioavailability of BCS class IV 
drug. Atovaquone was selected as a model drug. Formulations of a 
solid dispersion in a binary and ternary system with biosurfactant and 
synthetic surfactants were prepared and compared. The ternary 
system was proved to be better than the binary system for 
enhancement of dissolution rate. Atovaquone tablets prepared from 
physical mixture blend and solid dispersed products. Evaluated results 
indicated that addition of biosurfactant in the ternary system better 
than the physical mixture. In vivo study indicated the biosurfactant can 
also act as bioenhancer for BCS class IV drugs. However, detailed 
toxicology and stability studies are needed for the biosurfactant to be 
approved from regulatory authorities as the surface active agent. 
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